Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC (CONTESSA)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03326674 |
|
Recruitment Status :
Terminated
(The Sponsor has discontinued the development of tesetaxel)
First Posted : October 31, 2017
Last Update Posted : July 30, 2021
|
Sponsor:
Odonate Therapeutics, Inc.
Information provided by (Responsible Party):
Odonate Therapeutics, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | August 24, 2020 |
| Actual Study Completion Date : | June 28, 2021 |